Integrating antiretroviral therapy with TB treatment for co-infections reduces mortality

October 17, 2008

A South African treatment study conducted by researchers in the Department of Epidemiology at the Mailman School of Public Health shows that mortality among TB-HIV co-infected patients can be reduced by a remarkable 55%, if antiretroviral therapy (ART) is provided with TB treatment at the same time. The randomized, known as the SAPIT (Starting Antiretrovirals at three Points in Tuberculosis) trial, randomly assigned TB-HIV co-infected patients to receive ART. Patients who received ART together with their TB treatment (integrated treatment arm) were compared with patients assigned to receive ART upon completion of TB treatment (sequential treatment arm).

"The study shows that integrating TB and HIV treatment and care saves lives," says Salim S. Abdool Karim, MD, PhD, professor of clinical Epidemiology at the Mailman School of Public Health and director of the Centre for the AIDS Program of Research in South Africa (CAPRISA), who led the SAPIT trial. The trial was conducted at the CAPRISA eThekwini TB-HIV Clinic which is attached to the largest TB clinic in Durban, South Africa. The study was initiated in June 2005 and completed enrollment of 645 patients with TB and HIV co-infection in July 2008. It is estimated that about 70% of all TB patients in South Africa are infected with HIV, or about 250,000 of the 353,879 TB patients diagnosed in 2007.

As a result of the higher mortality rate in patients in the sequential treatment arm versus the mortality rate for those patients in the integrated treatment arm, the study's independent Safety Monitoring Committee recommended in their review of the trial in September 2008 that the sequential arm of the trial be stopped and that ART be initiated in this group as soon as possible. The Committee further recommended that the two sub-groups within the integrated treatment arm (early TB-HIV treatment and post-intensive phase TB-HIV treatment) should continue as per protocol.

Dr. Peter Piot, executive director of UNAIDS, commented: "These important results show that a ''two diseases, one patient, one response" integrated approach to TB/HIV treatment avoids unnecessary deaths from TB, the leading cause of death in people living with HIV in Africa". TB is the most common disease occurring in the late stages of HIV infection in southern Africa. As a result, many people throughout southern Africa are first identified as HIV infected when they develop TB. The findings of the SAPIT study call for the accelerated implementation of routine HIV testing in TB treatment services.

The SAPIT trial results provide compelling evidence to support the World Health Organization's call for the greater collaboration between TB and HIV treatment services and provide empiric evidence of the benefits from the initiation of antiretroviral therapy in TB-HIV co-infected patients. Dr Paul Nunn, of the Stop TB Department at the World Health Organization commented, "The results to date clearly show the urgent necessity to make ART available to HIV infected patients with TB worldwide." In South Africa alone, it would result in an additional 100,000 to 150,000 TB patients being initiated on ART resulting in about 10,000 deaths being averted each year.

Ambassador Mark Dybul, Coordinator of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) said: "Scaling up collaborative TB/HIV activities is a priority for PEPFAR. We remain committed to increasing screening for both HIV and TB, which will allow greater numbers of patients to benefit from these study results."

Columbia University's Mailman School of Public Health

---

---

	HIV-ASSOCIATED METABOLIC AND MORPHOLOGIC ABNORMALITY SYNDROME: Welcome therapy may have unwelcome effects (Postgraduate Medicine) by JTE Multimedia Recently, the remarkable progress of medical science in treatment of HIV and AIDS has been found to have a price tag attached. Physicians are encountering a litany of heretofore-unrecognized metabolic abnormalities and bizarre body-composition changes in patients receiving the antiretroviral therapy that has so greatly improved their lives. In this article, Dr Cohan describes changes that have been reported and identifies potential pathophysiologic mechanisms. In addition, he offers insight into treatment of this syndrome, which is only beginning to be recognized and studied. Cohan GR. HIV-associated metabolic and morphologic abnormality syndrome: welcome therapy may have unwelcome effects. Original Publication Date: April 2000
	A Decade of HAART: The Development and Global Impact of Highly Active Antiretroviral Therapy by Josï¿1/2 M Zuniga (Editor), Alan Whiteside (Editor), Amin Ghaziani (Editor), John G Bartlett (Editor) Highly active antiretroviral therapy (HAART) is a therapeutic intervention developed by clinicians and researchers in order to fight the HIV pandemic. It has contributed to a significant reduction in AIDS-related mortality and allowed many previously bed-ridden patients to live healthier, more productive lives. Until the advent of HAART in 1996, a diagnosis of HIV infection was considered a death sentence. A decade later, the disease has been transformed into a serious, yet potentially manageable, medical condition for thousands of people living with HIV/AIDS in the developed world - almost overnight creating a generation of "HIV Survivors" - and forged a global movement to ensure that its Lazarus-like benefit reaches millions more in the developing world. This book reviews the...
	Antidepressants and Labor Market Outcomes of Persons Living with HIV: An Analysis of Users of Highly-Active Antiretroviral Therapy in the United States: 1996-2004 by Omar Galarraga (Author), David S. Salkever (Author) The work examines the effect of antidepressants on the employment of HIV-positive persons receiving highly active antiretroviral therapy (HAART). It uses U.S. panel data (1996-2004) from the Women's Interagency HIV Study (WIHS) and the Multicenter AIDS Cohort Study (MACS). Regression models of employment control for: demographic characteristics, clinical indicators, physical and mental health summary measures and local area characteristics. Instrumental variables help identify antidepressant use. The results show that antidepressant use has a positive effect on the employment probability of women living with HIV. Among women receiving HAART, and controlling for individual and local area labor market characteristics, use of antidepressants is associated with a higher probability of being...
	Combination Therapy of AIDS (Milestones in Drug Therapy) by Erik De Clercq (Editor), Anne-Mieke Vandamme (Editor) An extensive assessment of combination therapy of AIDS. Main focus is put on the Highly Active Antiretroviral Therapy (HAART) but other therapies like salvage therapy are also discussed. The chapters cover efficacy, treatment, causes of treatment failure, clinical care, guidelines, pharmacology. The volume closes with an outlook on future perspectives.
	DESIGNING SALVAGE ANTIRETROVIRAL REGIMENS: Some basic guidelines and use of resistance testing (Postgraduate Medicine1) by JTE Multimedia In the field of HIV medicine, the term "salvage regimen" refers to one that is constructed for a patient in whom multiple previous regimens have been unsuccessful, for a wide variety of reasons. Although such regimens may have unproved efficacy, they are based on some solid scientific data or principles. In this article, the authors discuss the current state of genotyping and phenotyping used for resistance testing, the challenges involved in interpreting the data they provide, and factors to keep in mind when considering a switch to a different treatment regimen. Hardy WD, Hitt RS. Designing salvage antiretroviral regimens: some basic guidelines and use of resistance testing. Original Publication Date: April 2000
	Antiretroviral Therapy by American Society Microbiolgy (Publisher)
	Models for Life: Advancing Antiretroviral Therapy in Sub-Saharan Africa--Current African Issues 31 by Jeffrey V. Lazarus (Editor), Catrine Christiansen (Editor), Lise Rosendal Ostergaard (Editor), Lisa Ann Richey (Editor) Models for Life: Advancing antiretroviral therapy in sub-Saharan Africa is based on two conferences that were held in Copenhagen and Uppsala, in September 2004. The events brought together more than 70 key actors from Denmark, Sweden, and Uganda in the field of HIV/AIDS and its treatment—antiretroviral therapy. The conferences were unique in that each panel and the subsequent discussion brought together researchers, donors, and representatives from non-governmental organizations in order to link theory, operations research, and practice. The working paper covers a wide range of the issues that were brought up at the conferences, but focuses on the following three main topics: o access to antiretroviral therapy; o H\holistic approaches to providing...
	Williams' Basic Nutrition & Diet Therapy by Staci Nix (Author) Part of the popular LPN Threads Series, Williams' Basic Nutrition & Diet Therapy is the market leader for a reason: you get coverage of hot topics, emerging trends, and cutting edge research, plus all the essentials for providing the best nutrition care. Written in a clear, conversational style, the book begins with the fundamental concepts of nutrition and then applies those concepts to diverse demographic groups in different stages of life. You also learn how selected disease processes work, and how to help communities and individuals achieve health and healthy living. A free CD contains Nutritrac, a computer program that helps you analyze case studies and create customized client profiles.An engaging design includes colorful openers, illustrations, boxes, tables, and text layout....
	INITIATING HIV THERAPY: Timing is critical, controversial A concise synopsis of recent research data and current guidelines on when to initiate antiretroviral ... and side effects. (Postgraduate Medicine) by JTE Multimedia Currently available antiretroviral drug regimens are able to suppress HIV replication and allow CD4 recovery in the vast majority of patients with HIV infection. The challenge is to match each patient to the regimen that is most likely to durably suppress HIV replication enough to prevent resistance selection without causing treatment-limiting toxicities. It is also critical, but difficult, to know when to begin treatment relative to CD4 cell count and plasma viral load. In this article, Dr Volberding addresses the central questions surrounding antiretroviral treatment initiation and reviews some available treatment options. Original Publication Date: February 2004
	In HIV therapy adherence, almost isn't good enough.(Clinical Rounds): An article from: Skin & Allergy News by Michele G. Sullivan (Author) This digital document is an article from Skin & Allergy News, published by International Medical News Group on May 1, 2005. The length of the article is 488 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: In HIV therapy adherence, almost isn't good enough.(Clinical Rounds) Author: Michele G. Sullivan Publication: Skin & Allergy News (Magazine/Journal) Date: May 1, 2005 Publisher: International Medical News Group Volume: 36 Issue: 5 Page: 44(1) Distributed by Thomson...